SCHEMBL24072155

SCHEMBL24072155

CCN(CC)S(=O)(=O)c1ccc(S(=O)(=O)N2CCC[C@@H](C(=O)NC)C2)cc1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.73
NPC1 O15118 1/20 0.73
NR2F2 P24468 1/20 0.73
TDP1 Q9NUW8 1/20 0.61
KMT2A Q03164 5/20 0.61
MEN1 O00255 4/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
ALDH1A1 P00352 5/20 0.55
TP53 P04637 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.53
CYP2C19 P33261 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.51
TSHR P16473 1/20 0.51
USP2 O75604 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25282538 1.00 RAB9A (0.73) RAB9ANPC1NR2F2TDP1KMT2A
SCHEMBL24072138 0.89 TDP1 (0.78) RAB9ANPC1NR2F2TDP1KMT2A
SCHEMBL25284010 0.89 RAB9A (0.70) RAB9ANPC1NR2F2TDP1KMT2A
SCHEMBL24072131 0.89 RAB9A (0.70) RAB9ANPC1NR2F2TDP1KMT2A
SCHEMBL25286261 0.89 TDP1 (0.78) RAB9ANPC1NR2F2TDP1KMT2A
SCHEMBL25283718 0.88 RAB9A (0.76) RAB9ANPC1NR2F2TDP1KMT2A
SCHEMBL24072151 0.88 RAB9A (0.76) RAB9ANPC1NR2F2TDP1KMT2A
SCHEMBL25243079 0.88 RAB9A (0.76) RAB9ANPC1NR2F2TDP1KMT2A
SCHEMBL24072153 0.86 RAB9A (0.73) RAB9ANPC1NR2F2TDP1KMT2A
SCHEMBL25285648 0.86 RAB9A (0.73) RAB9ANPC1NR2F2TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212122-A1 MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-07-06 US disclosed
US-20230212122-A1 MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-07-06 US disclosed
WO-2021242753-A1 MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212122-A1 MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES TFAM, CS, FH RAB9A 839/4885NPC1 1157/4885NR2F2 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.